Publications

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer

3 November 2014/in Abstracts, Publications /by circlek

Design and Development of Novel, Highly-Selective HDAC6 Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt R., Silva F., Ward P., Whale A., Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A114.

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (NCRI Meeting)

3 November 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/d Inhibitors for the Treatment of Cancer.
Cecil A., Rogers H., Bone E., Colman L., Finan P., Haque K., Lensun L., Roitt S., Silva F., Ward P., Whale A. Shuttleworth S.
NCRI Meeting, Liverpool, UK, November 3, 2014, A143.

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer (San Diego)

5 April 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of Orally-Active, Selective PI3K-p110ß/δ Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A., Cecil A.R.L., Colman L., Fulton R., Haque K., Hill T.J., McGovern Y., Nodes W.J., Rogers H., Silva F.A., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-7.

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer

5 April 2014/in Abstracts, Publications /by circlek

Design and Development of a Novel Series of HDAC6-Selective Inhibitors for the Treatment of Cancer.
Shuttleworth S.J., Bone E.A; Cecil A.R.L., Colman L., Fulton R., Hill T.J., McCormick S., Nodes W.J., Rogers H., Silva F.A., Tomassi C.D., Whale A.D.
Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr LB-8.

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.

1 January 2011/in Publications /by circlek

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.
Shuttleworth SJ, Silva FA, Cecil AR, Tomassi CD, Hill TJ, Raynaud FI, Clarke PA, Workman P.
Curr Med Chem. 2011, 18(18), p2686-714.

Media Centre